secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-036264
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Q1 net loss $24.6M ($0.48/sh); cash $272.8M; LEGEND on track for BLA mid-2026
--------------------------------------------------------------------------------

- Net loss $24.6M ($0.48 per share) for Q1 ended Jan 31, 2025, vs $10.7M ($0.46) a year ago.
- Cash and marketable securities $272.8M; expected runway into 2027.
- Total operating expenses $26.6M, up from $10.8M, driven by LEGEND study costs and headcount.
- LEGEND pivotal cohort enrollment on track for BLA filing mid-2026; trial sites expanded to Europe/Asia.
- Amended protocol adds maintenance dosing for patients in CR at 12 months up to 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017025036264/0000950170-25-036264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017025036264/engn-20250310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-036264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer